CliffBio
small molecule

LIDOCAINE

LIDOCAINE

Loss of exclusivity—loss of exclusivity
CompanyIBSA Institut Biochimique →See this company's full patent-cliff portfolio

Drug detail

Brand nameLIDOCAINE
Active ingredientLIDOCAINE
Strength5%
Dosage formPATCH
RouteTOPICAL
ModalitySmall molecule
FDA approvalApril 2020
Marketing statusRX

More from IBSA Institut Biochimique

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

LIDOCAINE patent cliff — loss of exclusivity — | CliffBio